US/UK/Canada

Share

Contacts

  • Immunovia AB
    Medicon Village Scheelevägen 8 SE-223 63 Lund
    +46 46 275 60 00
    http://www.immunovia.com
    • Pick a time period -
    Tags ( Active)

    Immunovia publishes prospectus regarding preferential rights issue

    NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia publishes prospectus regarding preferential rights issue Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”). Publication of prospectusImmunovia’s prospectus, prepared in connection with

    Immunovia intends to launch a directed and preferential right issue

    NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia intends to launch a directed and preferential right issue SummaryImmunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares. Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK

    Immunovia Half-year report 2016

    “Immunovia reached several important milestones in the first six months of 2016. Good results were obtained in the American pancreas study that was carried out in collabo­ration with Knight Cancer Institute. Presentations made at the key global conferences concerning pancreatic cancer were very well received. A specially strong Scientific Advisory Board has been recruited, and involvement from the patient organization has increased. Furthermore, several significant agreements were signed with important cancer centres. The market introduction of IMMray™ PanCan –d, Immunovia’s diagnosis

    Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

    Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer.LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Dr. Marco Del Chiaro, a world recognized expert surgeon in pancreatic diseases, transplantation and robotic surgery has been appointed to the company’s Scientific Advisory Board. Marco Del Chiaro, MD, PhD, FACS is presently an associate professor of surgery and Head of Pancreatic Surgery Unit at

    Immunovia launches Swedish website

    LUND, Sweden ― Immunovia AB today introduces its website in Swedish as part of the efforts to grow its presence in the Scandinavian home markets. The company launched its global website one year ago and online reports show high total number of visitors from all around the world. However, since December last year, when the company was listed on Nasdaq First North in Stockholm, a lot of additional traffic to the website comes from the Swedish audience. “As we start to grow globally and expand into strategic markets, enabling local customers and investors to explore and learn about our

    Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

    Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLELUND, Sweden ― Immunovia AB announced today that the company has entered into an agreement with a large multinational life science company to run joint studies aimed at expanding the applications area of IMMray™, to autoimmune diseases. The market for SLE diagnosis is large as it is estimated that 5 million people suffer from SLE worldwide, with 100,000 new cases reported every year. As one of the most difficult to diagnose and monitor

    Immunovia Year-end report 2015

    "In 2015 Immunovia took important steps toward commercialisation of the world’s first blood-based test for cancer diagnosis, IMMray™ PanCan –d. We were able to prove, with 96% accuracy, that our test can diagnose the early stages of pancreatic cancer. In the second half of the year we signed a comprehensive agreement with Knight Cancer Institute at Oregon Health & Science University, USA, which during the year received a donation of USD 1 billion to achieve radical changes in cancer care globally through a focus on early diagnosis. Cooperation with Knight Cancer Institute will be decisive

    Immunovia approved for trading on Nasdaq First North as of December 1st, 2015

    Immunovia AB (publ) has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. Immunovia is a Swedish research company that has developed a new method for using a blood test to diagnose pancreatic cancer. With Immunovia’s test, diagnosis can be made earlier which substantially enhances the possibilities to treat the cancer. A new share issue of SEK 60 million before issue costs have been carried out before introduction on First North.Immunovia is a new exciting company in the life science sector on Nasdaq First North. With

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media